Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 17,108 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Carcinoma, Hepatocellular
Interventions: Atezolizumab, Bevacizumab, Sorafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 17 more

Conditions: Pain, Fever
Interventions: IV Acetaminophen; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 29 Days to 16 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Stanford, California • Ann Arbor, Michigan • Durham, North Carolina + 2 more

Conditions: Hodgkin Lymphoma
Interventions: Pembrolizumab, Involved Site Radiation Therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 54
States / cities: Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, ipratropium bromide / albuterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 10
States / cities: Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more

Conditions: Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions: Cisplatin, IMRT 6 weeks, IMRT 5 weeks; Drug · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 207
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 168 more

Conditions: Asthma
Interventions: Placebo, Setipiprant; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Los Angeles, California • Tallahassee, Florida • Normal, Illinois + 17 more

Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 409
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more

Conditions: Breast Cancer
Interventions: marimastat; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 25
States / cities: Scottsdale, Arizona • Chicago, Illinois • Urbana, Illinois + 22 more

Conditions: Melanoma
Interventions: Trametinib daily Until PD, CDX-3379 (ERBB3 antibody); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Mitral Valve Regurgitation (Degenerative or Functional)
Interventions: INNOVALVE system; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 21
States / cities: Los Angeles, California • Palo Alto, California • Naples, Florida + 15 more

Conditions: Relapsed Follicular Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, VELCADE, prednisone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 42
States / cities: Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 38 more

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: [18F]FAPI-74 PET/CT; Drug
Lead sponsor: SOFIE; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Cerritos, California • Duarte, California • Irvine, California + 15 more

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 13 Years and older
Enrollment: 2,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2013
U.S. locations: 19
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 14 more

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions: Seribantumab; Drug
Lead sponsor: Elevation Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more

Conditions: Advanced Parkinson's Disease
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 19
States / cities: Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more

Conditions: Prostate Cancer
Interventions: Zometa; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 56
States / cities: Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more

Conditions: Behçet's Syndrome
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Sacramento, California • Ormond Beach, Florida + 8 more

Conditions: Uterine Fibroids
Interventions: Proellex 25 mg, Proellex 50 mg; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 25
States / cities: Little Rock, Arkansas • Beverly Hills, California • San Diego, California + 17 more

Conditions: Knee Arthropathy
Interventions: Placement of an adductor canal nerve block; Procedure
Lead sponsor: Drexel University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Hyperpolarized xenon MRI; Combination Product
Lead sponsor: Xemed LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphedema
Interventions: 3M Coban 2 (Compression System), Comprilan; Device
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Evanston, Illinois • Columbia, Missouri • Philadelphia, Pennsylvania + 1 more

Conditions: Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
Interventions: Inhaled Technosphere Insulin; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more

Conditions: Systemic Lupus Erythematosus
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 21 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

TVMR With the INNOVALVE System Trial - Early Feasibility Study

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Longitudinal Study of Ocular Complications of AIDS (LSOCA)

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Defining the Optimal Location to Place an Adductor Canal Block

Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI

Assessment of 3M Oedema Reduction System in the Treatment of Lymphoedema Compared to Commercial Short-stretch Bandage

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children